142 related articles for article (PubMed ID: 6111093)
1. [Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Ringwald E; Lustig A; Moscovici M; Spiegel R; Vamos E
Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):318-24. PubMed ID: 6111093
[TBL] [Abstract][Full Text] [Related]
2. Use of bromocriptine to prevent puerperal lactation during neuroleptic treatment of chronic schizophrenia.
Wolf R
Pharmacopsychiatry; 1992 Sep; 25(5):240-2. PubMed ID: 1357683
[TBL] [Abstract][Full Text] [Related]
3. [Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
Ringwald E
Pharmakopsychiatr Neuropsychopharmakol; 1978 Nov; 11(6):294-8. PubMed ID: 33397
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine in tardive dyskinesia.
Häggström JE; Andersson U; Gunne LM
Pharmacopsychiatria; 1982 Sep; 15(5):161-3. PubMed ID: 6129649
[TBL] [Abstract][Full Text] [Related]
5. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
[TBL] [Abstract][Full Text] [Related]
6. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
[TBL] [Abstract][Full Text] [Related]
7. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
Lombertie ER; Durelle G; Fuseau A
Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
[TBL] [Abstract][Full Text] [Related]
8. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
9. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
10. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
11. Long term treatment of tardive dyskinesia.
Jus A; Jus K; Fontaine P
J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Yen YC; Lung FW; Chong MY
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
[TBL] [Abstract][Full Text] [Related]
13. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
14. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
[TBL] [Abstract][Full Text] [Related]
15. [Drug treatment of schizophrenic psychoses in puerperium].
Olbrich HM; Martin P
Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
[TBL] [Abstract][Full Text] [Related]
16. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms.
Naber D; Finkbeiner C; Fischer B; Zander KJ; Ackenheil M
Neuropsychobiology; 1980; 6(4):181-9. PubMed ID: 6104798
[TBL] [Abstract][Full Text] [Related]
18. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
Tripodianakis J; Markianos M; Garelis E
Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
[TBL] [Abstract][Full Text] [Related]
20. [The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients].
Elizur A; Segal Z; Yeret A; Aboo-Shach M; Ben-David M
Harefuah; 1979 Sep; 97(5-6):101-4. PubMed ID: 44254
[No Abstract] [Full Text] [Related]
[Next] [New Search]